Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Hawaii Biotech has acquired exclusive license to tick-borne encephalitis (TBE) and malaria virus vaccine technology and a non-exclusive license to recombinant protein expression technology from Merck.
Subscribe to our email newsletter
The technologies were developed by Hawaii Biotech and acquired by Merck in 2010.
Hawaii Biotech CEO Elliot Parks said the licenses would help in the development of vaccines for TBE, malaria, and other subunit vaccines for various infectious diseases.
"We are pleased with the working relationship we have established with Merck, appreciate their cooperation, and look forward to continuing the development of these vaccine candidates," Parks added.